{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:55:54Z","timestamp":1753890954737,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Kinetics of stress-related biological parameters were determined in acute coronary syndrome (ACS) patients undergoing complex cardiovascular rehabilitation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We determined platelet functionality in the absence\/presence of a selective alpha-2 adrenergic receptor inhibitor, atipemazole parallel with salivary cortisol levels at enrolment, and at 3- and 12-months follow-up in 75 ACS patients with percutaneous coronary intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Pharmacological\/non-pharmacological secondary prevention methods have been efficiently applied. Baseline aggregometry indicated platelet hyperactivity, decreasing gradually and being significantly reduced late, at 12 months (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05). Cortisol levels followed similar kinetics (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05). Baseline epinephrine-induced aggregations (EIA) significantly correlated with most of the other platelet agonists, even at subsequent time-points. Patients with upper-quartile EIA at enrolment (EIA-UQ) had significantly higher ADP- and collagen-induced aggregations at enrolment, at 3- and 12-months follow-up as well, indicating that high adrenergic response in the acute phase is accompanied by general platelet hyperactivity and predicts sustained platelet activation. In the EIA-UQ group higher cardiac biomarker release, elevated C-reactive protein and cortisol levels, and lower baseline left ventricular ejection fraction were detected.<\/jats:p><jats:p>Atipemazole significantly reduced platelet aggregation induced by several platelet agonists, being most potent and comparable to full <jats:italic>in vitro<\/jats:italic> P2Y<jats:sub>12<\/jats:sub> inhibition on collagen-induced aggregations (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05), indicating that catecholamines might serve as promt\/long-term modulators of platelet function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Despite effective CCR programme and dual antiplatelet therapy, prolonged activation of sympathetic neuroendocrine system and general platelet hyperactivity can be detected up to one year in ACS patients with high adrenergic platelet activity. Moreover, initial high adrenergic activity is accompanied by clinical parameters associated to increased cardiovascular risk, therefore early identification of these patients might support complex optimal long-term therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1338066","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T05:04:40Z","timestamp":1708491880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["High platelet adrenergic activity and concomitant activation of the pituitary\/medullar axis as alarming laboratory parameters in ACS survivors\u2014the STRESS-AMI study"],"prefix":"10.3389","volume":"11","author":[{"given":"Zal\u00e1n","family":"Guly\u00e1s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zs\u00f3fia","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Hajtman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Kohut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"K\u00f3sa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emese","family":"T\u00f3th-Zs\u00e1mboki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00f3bert G\u00e1bor","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"The Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1177\/2047487317704937","article-title":"Cardiac rehabilitation programme as a non-pharmacological platelet inhibitory tool in acute coronary syndrome survivors","volume":"24","author":"T\u00f3th-Zs\u00e1mboki","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/S0735-1097(02)02831-0","article-title":"Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention","volume":"41","author":"Mehta","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.108.812636","article-title":"Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up","volume":"119","author":"Marcucci","year":"2009","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1160\/TH14-03-0238","article-title":"How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors\u2014is an algorithm the answer?","volume":"113","author":"Siller-Matula","year":"2015","journal-title":"Thromb Haemost"},{"key":"B10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jjcc.2018.10.005","article-title":"Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation","volume":"73","author":"Verdoia","year":"2019","journal-title":"J Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1530\/EJE-07-0455","article-title":"Glucocorticoids and cardiovascular disease","volume":"157","author":"Walker","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S0140-6736(07)61305-1","article-title":"The cardiovascular toll of stress","volume":"370","author":"Brotman","year":"2007","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.bbi.2005.08.002","article-title":"Platelets, coronary heart disease, and stress","volume":"20","author":"Brydon","year":"2006","journal-title":"Brain Behav Immun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3109\/08037059409102247","article-title":"Sympathetic nervous system involvement in essential hypertension: increased platelet noradrenaline coincides with decreased \u03b2-adrenoreceptor responsiveness","volume":"3","author":"Kjeldsen","year":"1994","journal-title":"Blood Press"},{"key":"B15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1034\/j.1600-0609.2000.065006357.x","article-title":"Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo","volume":"65","author":"Von K\u00e4nel","year":"2000","journal-title":"Eur J Haematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1160\/TH08-03-0158","article-title":"Analysis of platelet \u03b12-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy","volume":"100","author":"B\u00e9res","year":"2008","journal-title":"Thromb Haemost"},{"key":"B17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/HCR.0b013e3181ac785f","article-title":"Does stress reduction change the levels of cortisol secretion in patients with coronary artery disease?","volume":"29","author":"Ryd\u00e9n","year":"2009","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2106\/00004623-195739020-00034","article-title":"The stress of life. Hans selye, New York, McGraw-hill book company, inc. 1956. $5.95","volume":"39","year":"1957","journal-title":"J Bone Jt Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/2047487317734323","article-title":"Prolonged hypothalamic-pituitary-adrenal axis activation after acute coronary syndrome in the GENESIS-PRAXY cohort","volume":"25","author":"Tang","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100623","DOI":"10.1016\/j.cpcardiol.2020.100623","article-title":"Cortisol-mediated stress response and mortality in acute coronary syndrome","volume":"46","author":"Aladio","year":"2021","journal-title":"Curr Probl Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0167-5273(92)90201-D","article-title":"Serum cortisol levels predict infarct size and patient mortality","volume":"37","author":"Bain","year":"1992","journal-title":"Int J Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1161\/01.CIR.45.4.736","article-title":"Serum cortisol, plasma free fatty acids, and urinary catecholamines as indicators of complications in acute myocardial infarction","volume":"45","author":"Prakash","year":"1972","journal-title":"Circulation"},{"key":"B23","first-page":"8","article-title":"Correlation between cortisol levels and myocardial infarction mortality among intensive coronary care unit patients during first seven days in hospital","volume":"36","author":"Nito","year":"2004","journal-title":"Acta Med Indones"},{"key":"B24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.psyneuen.2008.10.026","article-title":"Salivary cortisol as a biomarker in stress research","volume":"34","author":"Hellhammer","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/HCR.0000000000000225","article-title":"Patient characteristics predictive of cardiac rehabilitation adherence","volume":"37","author":"Gaalema","year":"2017","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/03007995.2018.1510385","article-title":"Assessment of adherence to medication in patients after myocardial infarction treated with percutaneous coronary intervention. Is there a place for newself-reported questionnaires?","volume":"35","author":"Kubica","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"B29","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/joim.12296","article-title":"Thrombosis formation on atherosclerotic lesions and plaque rupture","volume":"276","author":"Badimon","year":"2014","journal-title":"J Intern Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jcin.2013.06.011","article-title":"Response variability to P2Y12 receptor inhibitors","volume":"6","author":"Siller-Matula","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"B33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/emm.1999.7","article-title":"Co-activation of gi and gq proteins exerts synergistic effect on human platelet aggregation through activation of phospholipase C and Ca2+ signalling pathways","volume":"31","author":"Shah","year":"1999","journal-title":"Exp Mol Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.2174\/092986710792065018","article-title":"Regulators of platelet cAMP levels: clinical and therapeutic implications","volume":"17","author":"Noe","year":"2010","journal-title":"Curr Med Chem"},{"key":"B35","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1055\/s-0038-1660853","article-title":"Effects of acute stress on thrombosis","volume":"44","author":"Bentur","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"B36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MED.0000000000000328","article-title":"Salivary cortisol and cortisone in the clinical setting","volume":"24","author":"Blair","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.psyneuen.2018.10.015","article-title":"Salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate","volume":"101","author":"Bae","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2459\/JCM.0b013e328364100b","article-title":"Plasma cortisol and prognosis of patients with acute myocardial infarction","volume":"15","author":"Jutla","year":"2014","journal-title":"J Cardiovasc Med"},{"key":"B39","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/B978-0-7020-6896-6.00069-7","article-title":"Inflammation and atherothrombosis","volume-title":"Clinical Immunology","author":"Liuzzo","year":"2019"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jacc.2016.01.069","article-title":"Relationship between infarct size and outcomes following primary PCI","volume":"67","author":"Stone","year":"2016","journal-title":"J Am Coll Cardiol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1338066\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T05:04:43Z","timestamp":1708491883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1338066\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":40,"alternative-id":["10.3389\/fcvm.2024.1338066"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1338066","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"article-number":"1338066"}}